PB4008 Pharmacogenomics Syllabus:

PB4008 Pharmacogenomics Syllabus – Anna University PG Syllabus Regulation 2021

COURSE OBJECTIVES:

Upon successfully completing this course, students will:
• Describe the fundamental concepts of pharmacogenomics.
• Recognize how new technologies, such next-generation sequencing, are affecting the development and use of pharmacogenomics.
• Aware of the significance of pharmacogenomics and its use in clinical practise.

UNIT I PHARMACOGENOMICS AND PERSONALIZED MEDICINE

Historical aspects of Pharmacogenetics, Pharmacogenetics and Populations, Monogenic and Multigenic Variations of Drug Responses, personalized medicine, strategies for application of pharmacogenomics to customize therapy, Barriers, Future Perspectives.

UNIT II PHARMACOGENETICS OF ENZYMES AND RECEPTORS

Pharmacogenetics of two clinically important polymorphic enzymes, CYP2D6 and TPMT, nuclear receptors, cell surface receptors, Future Perspectives on the Pharmacogenetics of Drug Metabolism, Nuclear Receptors, Cell Surface Receptors.

UNIT III PHARMACOGENETICS OF DRUG TRANSPORTERS

Organic anion and cation transporter polypeptide family – OATP-B, OATP-C, OATP-8, OATP-D, OATP-E, OATP-F, OATP-H, OATP-I, OATP-J, and PGT OAT1, OAT2, OAT3; OCT1, OCT2, OCT3, PepT and MRP families- MDR1, MDR3, BSEP, MRP1, MRP3, MRP4, MRP5, MRP6, MRP8 BCRP protein.

UNIT IV TECHNOLOGIES IN PHARMACOGENOMICS

Single Nucleotide Polymorphism, SNP Analysis Technologies, Biochemistries, Hybridization-Based Approaches – Enzyme-Based Approaches, Combined Hybridization/Enzymatic Approaches, Detection Methods, Platforms

UNIT V PHARMACOEPIGENETICS

General principles of epigenetic regulation – epigenetic mechanisms, DNA methylation, methylated cytosine binding proteins, histone modifications, coordination of epigenetic machinery, epigenetic functions, genetic imprinting, x inactivation, geneome defence, epigenetics and human disease – therapeutic applications – HDAC inhibitors, DNMT inhibitors, CpG Oligonucleotides and Immune Response, Designer Transcription Factors

TOTAL: 45 PERIODS

COURSE OUTCOMES

The students will be able to
 Differentiate how individual genetic variations affect drug therapy outcomes, as well as therapeutic efficacy and toxicity.
 Describe how single nucleotide polymorphism functions as a biomarker for the assessment of disease, therapeutic response, and prognosis.
 As new tools based on genetics become available, use them, manage them, and decide on the best course of action.
 Use pharmacogenomics approaches to address issues in pharmaceutical care by using a specific pharmacological therapy.
 Be aware of the ethical and societal ramifications of genetic testing and the individualized pharmacological therapy that results from it.
 Recognize the effectiveness of different medications based on genetics and apply it to clinical research.

TEXTBOOKS

1. Pharmacogenetics: An Introduction and Clinical Perspective” edited by Joseph S. Bertino, et al. 2013.
2. Concepts in pharmacogenomics. Martin M. Zdanowicz. Bethesda, Md. American Society of Health-System Pharmacists, 2010.
3. Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response Beverly A. Teicher, Federico Innocenti, Springer, USA, 2008.
4. Gene-Environment Interactions: Fundamentals of Ecogenetics Costa, LG and Eaton DL., Wiley Press, 2006.

REFERENCES

1. Pharmacogenomics Werner Kalow, Rachel F Tyndale, Urs A Meyer, Marcel Dekker Inc., USA, 2001.
2. Pharmacogenomics in Drug Discovery and Development Second Edition Edited by Qing Yan PharmTao, Santa Clara, Springer New York, 2014.
3. Pharmacogenomics Challenges and Opportunities in Therapeutic Implementation second edition Edited by Y. W. Francis Lam Stuart A. Scott. Academic Press, 2019.
4. Pharmacogenomics in clinical therapeutics edited by Loralie J. Langman and Amitava Dasgupta, John Wiley & Sons, Ltd, 2012.